Group 1 - The core viewpoint of the report is that Xianruida Medical-B (06669) is given a "strong buy" investment rating due to its innovative capabilities and product strength, supported by the global platform of its controlling shareholder, Boston Scientific, which enhances performance certainty through collaboration in overseas expansion and new product development [1] Group 2 - Xianruida is a leading domestic company focused on providing comprehensive vascular intervention solutions, having launched the first knee and below DCB products in China, and is positioned at the forefront of the peripheral intervention field [1][2] Group 3 - The company has established a multi-technology platform since 2011, developing drug-coated balloon (DCB) and percutaneous transluminal angioplasty (PTA) products, achieving a comprehensive layout in the peripheral intervention field with over 30 listed products by H1 2025, covering vascular surgery, cardiology, nephrology, and neurology [2] Group 4 - The product lineup is structured in a "pyramid" model, with mature products like DCB and PTA balloons being the main revenue source, while growth products such as peripheral suction systems and radiofrequency ablation systems are expected to drive future revenue growth [3] Group 5 - A new three-year cooperation agreement was signed with Boston Scientific for 2026-2028, which includes global commercialization, product manufacturing, and R&D support, with projected sales to Boston Scientific reaching up to $30 million, $62 million, and $78 million in the respective years [4]

Core Viewpoint - The report from China Merchants Securities initiates coverage on Xianruida Medical-B (06669) with a "strong buy" rating, highlighting the company's innovative capabilities and product strength, as well as the performance certainty brought by the collaboration with its controlling shareholder, Boston Scientific, in overseas expansion and new product development [1]. Company Overview - Xianruida is a leading domestic innovative medical device platform focused on providing comprehensive vascular intervention solutions, having launched the first knee and below DCB products in China, and is positioned at the forefront of the peripheral intervention field [2]. Technology and Product Development - The company has been engaged in the R&D of PTA and DCB products since 2011, establishing a multi-technology platform that includes drug-coated technology, radiofrequency ablation technology, polymer material technology, and aspiration platform technology, achieving a comprehensive layout in vascular intervention with over 30 listed products by H1 2025, covering vascular surgery, cardiology, nephrology, and neurology [3]. Product Portfolio and Growth - The company has built a "pyramid" product group since the launch of its core knee DCB product in China in 2016, leading to steady revenue growth: 1. Mature products, including DCB and PTA balloons, are the main revenue sources, with the company holding the top market share in the domestic peripheral DCB sector and securing multiple procurement bids [4]. 2. Growth-stage products, such as peripheral aspiration systems and radiofrequency ablation systems, are in early volume expansion and are expected to contribute significantly to future revenue growth [4]. 3. The pipeline includes in-development projects like lower limb rapamycin DCB and IVL systems, covering mainstream departments and serving as a core source for medium to long-term growth [4]. Collaboration with Boston Scientific - In February 2023, Boston Scientific became the controlling shareholder of Xianruida with a 65% stake and signed a memorandum of understanding in June 2023. A new three-year cooperation agreement was signed for 2026-2028, which includes: 1. Global commercialization, sharing Boston Scientific's global channel resources, with projected sales to Boston Scientific capped at $30 million, $62 million, and $78 million for 2026, 2027, and 2028 respectively [5]. 2. Product manufacturing, providing OEM services with projected transaction amounts of $1 million, $1 million, and $3 million for the same years [5]. 3. Product R&D, with mutual support and CSO services [5].

Core Viewpoint - Xianruida is a leading domestic innovative medical device platform focused on providing comprehensive vascular intervention solutions, having launched the first knee and below DCB products in China, and is positioned at the forefront of the peripheral intervention field [1] Group 1: Product Development and Market Position - The company has established a multi-technology platform since 2011, developing PTA and DCB products, and has over 30 listed products as of H1 2025, covering vascular surgery, cardiology, nephrology, and neurology [1] - The product lineup includes mature products like DCB and PTA balloons, which are the main revenue sources, with the company holding the number one market share in the domestic peripheral DCB sector [2] - Growth-stage products such as peripheral suction systems and radiofrequency ablation systems are expected to drive future revenue growth due to their early-stage market penetration [2] Group 2: Strategic Partnerships and Future Outlook - In February 2023, Boston Scientific became the controlling shareholder of Xianruida, holding 65%, and a new three-year cooperation agreement was signed in December 2025, focusing on global commercialization, manufacturing services, and R&D collaboration [3] - The agreement includes projected sales to Boston Scientific of up to $30 million, $62 million, and $78 million from 2026 to 2028, and manufacturing service transactions of up to $1 million, $1 million, and $3 million in the same period [3] - The company is expected to achieve net profits of 120 million, 220 million, and 320 million yuan from 2025 to 2027, with year-on-year growth rates of 137.7%, 73.3%, and 49.7%, respectively, and a strong investment recommendation is given based on its innovative capabilities and strategic partnerships [3]

Macro Strategy - The LPR remained unchanged in September, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, reflecting a stable monetary policy in China [3] - A-shares experienced a high-level fluctuation with the Shenzhen Component Index rising by 1.06% and the ChiNext Index increasing by 1.96% during the week of September 22-26, 2025, driven by positive market sentiment and expectations of favorable policies [4] Industry Overview - The semiconductor and wind power equipment sectors showed strong performance with weekly increases of 7.64% and 6.00% respectively, while the tourism and hotel sectors faced declines of -11.65% and -8.38% [6] - The communication equipment and components sectors have seen cumulative gains of 95.45% and 91.96% respectively since the beginning of 2025 [6] North Exchange Market - As of September 26, 2025, the North Exchange had 277 listed stocks, with an average total market value of 883.56 billion, a decrease of 4.14% from the previous week [9] - The liquidity in the North Exchange decreased, with average trading volume dropping by 20.67% to 9.10 billion shares [11] New Materials Industry - The rare earth magnetic materials sector declined by 1.54% this week, underperforming the benchmark [15] - Prices for rare earth minerals continued to adjust, with mixed carbonated rare earth ore prices falling by 2.63% to 3.57% [16] Medical Consumables Industry - Aibo Medical's extended depth of focus intraocular lens received approval, indicating growth potential in the high-end segment of the artificial lens market driven by an aging population [21] - The market for high-value consumables is expected to benefit from recent policy changes and the ongoing demand for diverse medical supplies [24]

Market Overview - The three major indices opened lower, with the ChiNext index down 0.79%. As of the market opening, the Shanghai Composite Index was at 3804.48 points, down 0.45%; the Shenzhen Component Index was at 13037.08 points, down 0.63%; and the ChiNext index was at 3089.90 points, down 0.79% [1] Economic Data - In August, the total electricity consumption in China reached 10,154 billion kilowatt-hours, a year-on-year increase of 5.0%, with industrial electricity consumption accounting for nearly 60% and manufacturing electricity consumption growing by 5.5% year-on-year [1] - From the Ministry of Industry and Information Technology, it was reported that from January to July 2025, the sales of new passenger cars equipped with combination driving assistance systems reached 7.76 million units, with a penetration rate of 62.6%, an increase of 5.7 million units and 40 percentage points compared to the same period in 2021 [1] Corporate Announcements - Ganli Pharmaceutical announced a supply framework agreement related to insulin with a minimum value of 3 billion yuan [2] - Wolong Nuclear Materials announced a planned investment of 1 billion yuan to establish a new materials project in Suzhou [2] - Hualing Cable announced a plan to acquire control of SanZhu Intelligent for no more than 270 million yuan, accelerating entry into the robotics sector [2] - Shengmei Shanghai announced the delivery of its first KrF process front-end coating and developing equipment to a leading logic wafer factory in China [4] - Dongshan Precision announced plans to issue H-shares and list on the Hong Kong Stock Exchange [5] - Aowei New Materials completed the transfer of shares, with the controlling shareholder changing to a holding platform established by an affiliate of Zhiyuan Robotics [6] - Baijin Medical announced that its radiofrequency ablation system has entered the special review process for innovative medical devices [13] Market Sentiment - Zhongyuan Securities noted that the A-share market is experiencing a rebound and wide fluctuations, with banks, precious metals, engineering construction, and shipping ports performing well, while tourism, small metals, real estate, and software development sectors lagged [9] - Dongguan Securities observed that the A-share market is in a consolidation phase, with structural opportunities still significant, particularly in the semiconductor industry, which continues to show strength [10]

Group 1: Electricity Consumption - In August, the total electricity consumption reached 10,154 billion kilowatt-hours, marking a year-on-year increase of 5.0% and setting a historical record for the second consecutive month above 1 trillion kilowatt-hours [2]. Group 2: Regulatory Developments - The State Administration for Market Regulation announced that issues of false marketing and counterfeit goods are prominent in the live e-commerce sector, leading to the drafting of the "Live E-commerce Supervision Management Measures," which will be officially released soon [2]. - The National Internet Information Office has taken action against platforms like Toutiao and UC for failing to manage harmful content, resulting in penalties including warnings and demands for corrections [2]. Group 3: Corporate Announcements - Rili Pharmaceutical signed a supply framework agreement worth no less than 3 billion yuan [6]. - Woler Materials plans to invest up to 1 billion yuan in a new materials project [6]. - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange [6]. - Olin Bio is also planning to issue H-shares for listing on the Hong Kong Stock Exchange [6]. - Shima Co. intends to repurchase shares worth between 100 million to 200 million yuan [6]. - Guaihuo Communication plans to repurchase shares worth between 75 million to 150 million yuan [6].

Market Overview - The Shanghai Composite Index closed at 3821.83, down 0.18%, while the Shenzhen Component Index fell by 0.29% to 13119.82. The ChiNext Index increased by 0.21% to 3114.55, and the STAR Market 50 Index decreased by 0.10% to 1407.30. The CSI 300 Index also saw a slight decline of 0.06%, closing at 4519.78 [1][7]. Industry Dynamics - In August 2025, China's domestic gaming market revenue was 29.263 billion yuan, a year-on-year decrease of 13.01%. The decline was attributed to the high revenue base from the previous year due to the success of the game "Black Myth: Wukong" [5][23]. - OpenAI and NVIDIA announced a strategic partnership to build and deploy AI data centers with a capacity of at least 10 gigawatts, with NVIDIA planning to invest up to 100 billion USD to support this initiative [5][24]. - In August 2025, China's engineering machinery exports increased by 15.4% year-on-year, with total exports amounting to 5.115 billion USD. The total trade volume for engineering machinery in the first eight months of 2025 reached 40.398 billion USD, reflecting an 11% year-on-year growth [5][26]. Company Updates - Bairen Medical (688198.SH) has entered the special review process for its radiofrequency ablation system, which is designed for treating atrial fibrillation [5][28]. - Xiangcai Co., Ltd. (600095.SH) announced that the audit and due diligence related to its major asset restructuring have been largely completed, with further steps to be taken in accordance with legal regulations [5][31].

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Core Viewpoint - The company, Baifen Medical, has announced that its self-developed radiofrequency ablation system has received approval from the National Medical Products Administration (NMPA) to enter the special review process for innovative medical devices [2] Group 1 - The radiofrequency ablation system is a product developed independently by the company [2] - The approval marks a significant step for the company in the medical device sector [2] - The entry into the special review process indicates the potential for expedited evaluation and market entry [2]

Mergers and Acquisitions - Hualing Cable plans to acquire control of San Bamboo Intelligent for no more than 270 million yuan, with San Bamboo being a leading provider of industrial connection product solutions in the industry [1] Share Buybacks - Shennma Co. intends to repurchase shares worth between 100 million and 200 million yuan [2] - Fenghuo Communication plans to repurchase shares worth between 75 million and 150 million yuan and will cancel the repurchased shares [2] Investment Cooperation and Operational Status - Yuntian Lifei's self-developed AI-driven product, Luka Doctor AI plush toy, is expected to launch by the end of 2025. The company is also developing the next-generation "brain" chip, DeepXBot series, to enhance humanoid robots' perception, cognition, decision-making, and control tasks [3] - Zhejiang Haideman is in the prototype trial phase for its humanoid robot and robotic dog projects [3] - Haimuxing is among the first in the industry to achieve the "oxide + lithium metal anode" technology route and has completed the commercial closed loop for lithium metal solid-state batteries, which are currently being delivered in batches [3] - Guomai Culture is investing in the film "The Starry Sky of the Three Kingdoms Part One," set to premiere on October 1 [3] - Visionox plans to use Suzhou Guoxian as the project company to carry out preliminary work for the Kunshan Global New Display Industry Innovation Center project [4] - Fola New Materials has collaborated with several domestic and international dexterous hand and humanoid robot companies [5] - Jiuwu High-Tech signed a procurement contract for a membrane treatment system worth 81.5 million yuan with Guotou Xinjiang Lithium Industry Co., Ltd. [6] - Wolker Materials' controlling subsidiary plans to invest 1 billion yuan in the construction of the Kote (Suzhou) New Materials Project [7] - Heng Rui Pharmaceutical's SHR7280 tablet application for marketing approval has been accepted by the National Medical Products Administration, with no oral GnRH antagonists approved in the domestic and international assisted reproductive fields [7] - Ganli Pharmaceutical signed a "Technology Transfer and Supply Agreement" with FZ and BIOMM for a production partnership plan in Brazil, with a total contract value expected to be no less than 3 billion yuan (including tax) [7] - Sinovac Biotech's human interferon α1b inhalation solution has been included in the list of breakthrough therapeutic varieties [8] - Baijin Medical's radiofrequency ablation system has entered the special review process for innovative medical devices [8] - Jiangbolong anticipates an increase in demand for server NAND market inventory in the second half of the year, with storage market prices expected to rise in the fourth quarter. The company's enterprise-level PCIe SSD and RDIMM products have begun bulk imports to leading domestic enterprises [8] - Jingzhida has completed its annual target ahead of schedule for the high-speed FT testing machine, with steady progress on the KGSD CP testing machine, continuously iterating and upgrading in conjunction with storage industry technology solutions [8] - Fuhuang Steel Structure signed a strategic cooperation agreement with the Twenty-Second Metallurgical Group [9] - Poly Development plans to issue company bonds not exceeding 15 billion yuan [10] - Shangwei New Materials has completed the transfer of shares and the controlling shareholder has changed to a holding platform established by an affiliate of Zhiyuan Robotics [11]